## Maristella Saponara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7523135/publications.pdf

Version: 2024-02-01

71 1,682 23
papers citations h-index

72 72 72 2429
all docs docs citations times ranked citing authors

38

g-index

#	Article	IF	Citations
1	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. European Journal of Human Genetics, 2014, 22, 32-39.	2.8	90
2	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Laboratory Investigation, 2010, 90, 1285-1294.	3.7	77
3	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	10.7	73
4	Insulinâ€ike growth factor 1 receptor expression in wildâ€type GISTs: A potential novel therapeutic target. International Journal of Cancer, 2009, 125, 2991-2994.	5.1	70
5	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14, 685.	2.6	70
6	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacological Research, 2013, 68, 1-6.	7.1	64
7	Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 778-785.	2.5	63
8	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. Molecular Cancer Research, 2017, 15, 553-562.	3.4	53
9	Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncology Reports, 2009, 21, 1359-66.	2.6	52
10	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. European Journal of Cancer, 2021, 157, 250-258.	2.8	52
11	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics, 2015, 16, 892.	2.8	48
12	Gastrointestinal stromal tumors: report of an audit and review of the literature. European Journal of Cancer Prevention, 2009, 18, 106-116.	1.3	45
13	Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer, 2012, 12, 231.	2.6	44
14	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	7.0	44
15	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genetics in Medicine, 2015, 17, 391-395.	2.4	41
16	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncolmmunology, 2019, 8, e1617588.	4.6	41
17	Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses. JACC: Cardiovascular Imaging, 2020, 13, 2400-2411.	5.3	40
18	<scp>HSPA</scp> 8 as a novel fusion partner of <scp>NR</scp> 4 <scp>A</scp> 3 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes and Cancer, 2017, 56, 582-586.	2.8	38

#	Article	IF	Citations
19	(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. European Journal of Cancer, 2017, 70, 1-11.	2.8	37
20	Current status of the adjuvant therapy in uterine sarcoma: A literature review. World Journal of Clinical Cases, 2019, 7, 1753-1763.	0.8	34
21	Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors, 2011, 3, 51-53.	0.6	29
22	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. International Journal of Molecular Sciences, 2018, 19, 732.	4.1	29
23	18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879356.	3.2	28
24	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 2016, 8, 1347-1366.	2.1	23
25	Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology, 2011, 59, 1071-1080.	2.9	22
26	Microscopic Margins of Resection Influence Primary Gastrointestinal Stromal Tumor Survival. Oncology Research and Treatment, 2012, 35, 645-648.	1.2	22
27	Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RASâ€P WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642.	2.8	22
28	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World Journal of Gastroenterology, 2014, 20, 7049.	3.3	22
29	Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?. Journal of Cancer Research and Clinical Oncology, 2008, 134, 625-630.	2.5	21
30	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 731-739.	3.2	20
31	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics Journal, 2019, 19, 390-400.	2.0	20
32	Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. Anticancer Research, 2020, 40, 1229-1238.	1.1	20
33	Molecular characterization of metastatic exon $11$ mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRÎ $\pm$ genotype evaluated by next generation sequencing (NGS). Oncotarget, 2015, 6, 42243-42257.	1.8	20
34	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Tumor Biology, 2016, 37, 13413-13423.	1.8	19
35	Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare Tumors, 2011, 3, 153-154.	0.6	18
36	Pharmacological therapies for Liposarcoma. Expert Review of Clinical Pharmacology, 2017, 10, 361-377.	3.1	17

#	Article	IF	CITATIONS
37	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget, 2017, 8, 60036-60045.	1.8	17
38	Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Anti-Cancer Drugs, 2012, 23, 567-572.	1.4	16
39	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST. Frontiers in Oncology, 2020, 10, 504.	2.8	16
40	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology, 2020, 47, 302-304.	2.2	15
41	Genetic aberrations and molecular biology of cardiac sarcoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091849.	3.2	13
42	Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature. Cancer Investigation, 2021, 39, 9-14.	1.3	12
43	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	2.8	11
44	Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncology, 2014, 10, 2045-2059.	2.4	10
45	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, 20, 139-148.	7.2	10
46	Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor. Anti-Cancer Drugs, 2018, 29, 589-595.	1.4	10
47	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Frontiers in Immunology, 2020, 11, 851.	4.8	10
48	Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clinical Sarcoma Research, 2014, 4, 9.	2.3	9
49	Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Reports in Oncology, 2012, 5, 651-656.	0.7	7
50	Late recurrences of gastrointestinal stromal tumours (GISTs) after 5Âyears of follow-up. Medical Oncology, 2012, 29, 144-150.	2.5	7
51	The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. Expert Review of Anticancer Therapy, 2016, 16, 473-484.	2.4	7
52	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. World Journal of Clinical Cases, 2019, 7, 3018-3026.	0.8	7
53	Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. International Journal of Surgery Case Reports, 2013, 4, 7-10.	0.6	6
54	Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncology Letters, 2014, 8, 1793-1799.	1.8	6

#	Article	IF	Citations
55	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097700.	3.2	6
56	Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Targeted Oncology, 2012, 7, 243-246.	3.6	5
57	Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. Oncology Letters, 2012, 3, 677-681.	1.8	5
58	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anti-Cancer Drugs, 2016, 27, 353-363.	1.4	5
59	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib. Scientific Reports, 2019, 9, 2172.	3.3	5
60	Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. Integrative Cancer Therapies, 2020, 19, 153473541990055.	2.0	5
61	What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. Minerva Surgery, 2017, 72, 219-236.	0.6	5
62	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. International Journal of Genomics, 2018, 2018, 1-9.	1.6	4
63	A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach. Clinical Medicine Insights: Oncology, 2018, 12, 117955491878247.	1.3	4
64	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. International Journal of Molecular Sciences, 2018, 19, 1855.	4.1	4
65	Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. Respiratory Medicine Case Reports, 2019, 28, 100961.	0.4	4
66	Complete radiological response to first-line regorafenib in a patient with abdominal relapse of <i>BRAF V600E</i> mutated GIST. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092730.	3.2	4
67	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, $11,778461$ .	2.8	4
68	Primary malignant pericardial tumour in Lynch syndrome. BMC Cancer, 2020, 20, 191.	2.6	3
69	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2018, 36, 11534-11534.	1.6	1
70	Management of Patients with Gastrointestinal Stromal Tumor in Clinical Practice in Italy: A Critical "Event Tree Model―Analysis of Decision-Making Processes and Outcomes. Tumori, 2010, 96, 219-228.	1,1	0
71	Integrate whole genomic study of KIT/PDGFRA wild-type (WT) GIST Journal of Clinical Oncology, 2014, 32, 10513-10513.	1.6	0